Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2130761 | Experimental Cell Research | 2011 | 7 Pages |
Abstract
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds. By using the framework of anti-EGFR inhibitors as treatment for colorectal cancer patients, we will review the knowledge we have reached until now in improving the development of a personalized cancer therapy and we will try to indicate the future challenges this field will face in the future.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Loredana Vecchione, Bart Jacobs, Nicola Normanno, Fortunato Ciardiello, Sabine Tejpar,